Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Street Assesses AbbVie

This article was originally published in The Pink Sheet Daily

Executive Summary

With a market cap of a Bristol-Myers or Eli Lilly, AbbVie is worth more in early trading than the remaining Abbott. If it can keep growing Humira sales while making its pipeline pay-off, it will be the poster child for slimmed-down and refashioned pharma.

You may also be interested in...



Uptick In 4Q 2013 M&A Deal-Making Likely To Continue Into 2014, PwC Report Predicts

Earn-outs and other deal tools help bridge value gaps and share risk, enabling more deals to be finalized, report says. However, pharma is seeing increased M&A competition from biotechs looking to diversify and increase scale.

AbbVie Sets Out To Win Over Investors In Its First Financial Call

Management highlighted the ongoing growth potential of Humira and a late-stage pipeline that it says has the ability to generate between $4 billion and $6 billion of growth during the new pharmaceutical company’s first financial call with investors.

AbbVie CEO Emphasizes Humira Growth Plans, Potential Of HCV Program

AbbVie should appeal to long-term investors due to its sustainable business base and plan to issue and increase dividends over time, says CEO Richard Gonzalez.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS073663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel